Patheon has entered a sales and marketing agreement with Italy’s BSP Pharmaceuticals, a developer and manufacturer of cytotoxic pharmaceutical products. Patheon will promote BSP’s cytotoxic manufacturing capacity and development services and Aldo Braca, president, Patheon Europe, will serve as president and chief executive officer of BSP Pharmaceuticals until a successor is named. For a transitional period, Mr. Braca will fill both roles.     “Cytotoxic manufacturing represe...